Celcuity closed at $69.24 on Nov 4, down 0.69%, 52.2% below its 52-week closing high. Volume of 1.2M shares was 0.67× its 20-day average (below normal).
Split-adjusted performance: -2.8% over one month, -50.3% over six months, -7.9% over one year.
Short interest was 10.3M shares at the Oct 15 settlement, down 6.6% from the prior report (25.7% of float, 5.8 days to cover).
No reported quarters with price history yet.
Percentile among 24 companies (100 = best)
Industry medians: 6-month return +36.9%, revenue growth +25.0%, net margin −4.0%, P/E 32.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CELCCelcuity | $69.24 | −0.69% | −50.3% | — | — | — | $3.39B | |
| VCYTVeracyte | $52.52 | +4.43% | +27.5% | +15.5% | 17.0% | 36.9 | $4.22B | Compare |
| CDNACareDx | $85.86 | −2.95% | +309.8% | +39.3% | 13.8% | 35.1 | $4.51B | Compare |
| BLLNBillionToOne | $113.89 | +3.11% | +39.9% | — | 7.4% | — | $5.37B | Compare |
| FTREFortrea Holdings | $20.83 | −0.57% | +33.2% | −1.4% | 0.1% | — | $2.01B | Compare |
| RDNTRadNet | $80.26 | +9.67% | +36.9% | +25.0% | 1.2% | — | $6.32B | Compare |
| GRALGRAIL | $143.66 | +3.03% | +128.9% | +25.7% | −246.7% | — | $6.42B | Compare |
| PSNLPersonalis | $15.79 | +0.25% | +160.1% | +30.0% | −141.7% | — | $1.69B | Compare |
| LMRILumexa Imaging Holdings | $13.10 | +16.76% | +27.4% | — | 1.0% | — | $1.26B | Compare |
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
